Shriti Vadera - Astrazeneca PLC Non-Executive Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 25px;;'>AS</div>
AZN -- USA Stock  

Earnings Report: April 24, 2020  

Ms. Shriti Vadera is no longer NonExecutive Independent Director of AstraZeneca PLC., effective from 31 December 2018. Skills and experience Shriti has significant knowledge of global finance, emerging markets and public policy. She has advised governments, banks and investors on the Eurozone crisis, the banking sector, debt restructuring and markets. She is a member of the G20 CEO Advisory Group and of the International Advisory Council of Asia House. Shriti is also Chairman of the European Financial Services Chairmans Advisory Committee, The City UK. She has served as a Minister in the UK Cabinet Office, and Business and International Development Departments. She has also served on the Council of Economic Advisers, HM Treasury, where she focused on business and international economic issues. Prior to that, Shriti spent 14 years in investment banking with SG WarburgUBS. Other appointments Shriti is Chairman of Santander UK plc and Senior Independent Director of BHP Billiton.
Age: 55  Director Since 2011      
(44) 1223 352 858  www.astrazeneca.com

Management Efficiency

The company has Return on Asset of 0.03 % which means that on every $100 spent on asset it made $0.03 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.17 % implying that it generated $0.17 on every 100 dollars invested.
The company has 20.31 B in debt with debt to equity (D/E) ratio of 148.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Astrazeneca PLC has Current Ratio of 0.9 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Don CornwellPfizer
Erik FyrwaldEli Lilly And Company
Kathi SeifertEli Lilly And Company
Harish ManwaniGilead Sciences
Etienne DavignonGilead Sciences
Wyllie CornwellPfizer
Ian DavisJohnson Johnson
Patrick OSullivanAllergan Plc
Joseph EchevarriaPfizer
John MadiganGilead Sciences
Mark McClellanJohnson Johnson
Susan LindquistJohnson Johnson
Lewis CampbellBristol Myers Squibb Company
Mary ColemanJohnson Johnson
Suzanne JohnsonPfizer
Deryck MaughanGlaxoSmithKline PLC
Dennis AusielloPfizer
William KaelinEli Lilly And Company
Pamela CraigMerck Company
Kelly KramerGilead Sciences
Jennifer DoudnaJohnson Johnson

Company Summary

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Astrazeneca PLC (AZN) is traded on BATS Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom and employs 64,400 people. Astrazeneca PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

Astrazeneca PLC Leadership Team

Marc Dunoyer, Chief Financial Officer, Executive DirectorView
Sherilyn McCoy, Non-Executive Independent DirectorView
Genevieve Berger, Non-Executive Independent DirectorView
Luke Miels, Executive Vice-President GPPSView
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines DevelopmentView
Paul Hudson, Executive Vice President North AmericaView
Nazneen Rahman, Non-Executive Independent DirectorView
Jose Baselga, Executive Vice President - Research & Development OncologyView
JeanPhilippe Courtois, Non-Executive Independent DirectorView
Thomas Larsen, IR Contact OfficerView
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance OfficerView
Tony Mok, Non-Executive Independent DirectorView
Mark Mallon, Executive Vice President InternationalView
Fiona Cicconi, Executive Vice President - Human ResourcesView
Deborah DiSanzo, Non-Executive Independent DirectorView
Shriti Vadera, Non-Executive Independent DirectorView
Leif Johansson, Non-Executive Independent Chairman of the BoardView
Leon Wang, Executive Vice President - International and China PresidentView
Ann Cairns, Non-Executive DirectorView
Adrian Kemp, Company SecretaryView
Cornelia Bargmann, Non-Executive DirectorView
Tim JacksonSmith, Non-Executive DirectorView
Michel Demare, Non-Executive DirectorView
Graham Chipchase, Senior Non-Executive Independent DirectorView
David Smith, Executive VP of Operations and Information ServicesView
Pascal Soriot, CEO, Executive Director and Member of Disclosure CommitteeView
Pam Cheng, Executive Vice-President of Operations and Information TechnologyView
Baroness Vadera, Non-Executive Independent DirectorView
Philip Broadley, Non-Executive Independent DirectorView
Narayan Seshadri, Independent DirectorView
Jeffrey Pott, General CounselView
Ruud Dobber, Executive Vice President, BioPharmaceuticals BusinessView
David Fredrickson, Executive Vice-President Global Head Oncology Business UnitView
Bahija Jallal, Executive Vice President MedImmuneView
Rudolph Markham, Non-Executive Independent DirectorView
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticalsView
Weiying Wang, Non-Executive DirectorView
Bruce Burlington, Non-Executive Independent DirectorView
Marcus Wallenberg, Non-Executive DirectorView
Iskra Reic, Executive Vice-President EuropeView

Stock Performance Indicators

Current Sentiment - AZN

Astrazeneca PLC Investor Sentiment

Predominant part of Macroaxis users are presently bullish on Astrazeneca PLC. What is your sentiment towards investing in Astrazeneca PLC? Are you bullish or bearish?
98% Bullish
2% Bearish

Astrazeneca PLC Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Astrazeneca PLC and Allergan Plc. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.